Identifying lifetime hypomanic symptoms in patients currently presenting with depression.
Screening for Bipolar II disorder and other bipolar spectrum conditions.
Differentiating Bipolar Disorder from Major Depressive Disorder (MDD).
Evaluating historical periods of high energy, mood elevation, or increased activity.
Section 2
Formula & Logic
Scoring Component
The HCL-32 consists of 32 Yes/No items. The score is the total number of "Yes" responses. The scale focuses on the "high" periods (different from the usual state).
Thresholds
Score ≥ 14
Suggested cutoff for Bipolar II
Sensitivity
High (ranges 80%–90%)
Specificity
Moderate (lower in psychiatric populations)
Section 3
Pearls/Pitfalls
Lifetime Perspective
The HCL-32 is a "lifetime" retrospective tool. It is crucial to instruct patients to think back to periods where they felt "higher than usual" or "differently active," regardless of how they feel currently.
Clinical Pearls
A score of 14 or more identifies about 80% of patients with bipolar disorder.
Factors like increased creativity, talkativeness, and reduced sleep are core indicators even if the patient did not find them distressing at the time.
False positives are possible in patients with borderline personality disorder or ADHD; clinical correlation is necessary.
Section 4
Next Steps
Next Steps
01
Score ≥ 14: Conduct a directed clinical interview exploring the duration and functional impact of the reported "high" periods.
02
Treatment Implication: High scores suggest a bipolar substrate; utilize caution with antidepressant monotherapy to avoid cycle acceleration.
03
Collateral History: Re-evaluate the HCL-32 items with a family member if the patient has limited insight into their "up" periods.
Section 5
Evidence Appraisal
Primary Reference
The Juhl checklist—HCL-32: a new self-assessment tool for hypomania
Angst J et al. • Journal of Affective Disorders. 2005;Vol 88, Issue 2. pp. 217-233. The original validation of the HCL-32.
Section 6
Literature
Jules Angst
Developed by Dr. Jules Angst and colleagues at the Zurich University Psychiatric Hospital. It is one of the most widely used research and clinical tools for the bipolar spectrum.
